From The Sun 24 hours of May 29, 2010: The
Nerviano Medical Sciences, the cancer research center on the outskirts of Milan, "divorced" by Pfizer and is on the market seeking investors. Thus ends a troubled story, and you open a new chapter for the cancer center which employs 530 engineers and 170 scientists. A contract, the one with the Americans, who reinforced the benefits of studies of the Lombard because Pfizer had a right of first refusal in respect of research results (technically a right of first refusal). A clause which in practice makes it less attractive the investment of third parties. Yesterday, the company president, Alberto Sciumè, flew to Washington to sign the separation from the time a shareholder in a U.S. multinational, also reached an agreement brokered by the Italian Embassy in the capital. An agreement, however, is only a starting point because Nerviano is in a state of great economic need, with only 10 million euro in cash needed to go only a few months. The idea is then to seek investors willing to bet on, or center, but it is a less desirable form an alliance with pharmaceutical partners. But how valuable search assets of nerves? Among the various molecules in the study is the Danusertib, active in the fight against lung cancer, already tested in humans, with a value potential (if successfully concluded Phase 2) ranging from 400 to 800 million euro. Meanwhile, however, it seems to be consuming another divorce: that between nerve and its research director, Francesco Colotta, which by July should allow laboratories.
Read the original site of Il Sole 24 ore
0 comments:
Post a Comment